Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arizona for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arizona only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arizona (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Iyad Hamarneh (NPI 1427268259)

Field	Value
Entity Type	Individual
Organization	Iyad Hamarneh
Address	5430 Landmark Ln
City	Prescott
State	AZ
ZIP	86301
Taxonomy	Medical Oncology Physician
NPI Enumerated	May 23, 2007

Payer Source	Total Paid
Medicare	$3.5M
Medicaid	$0

Key Findings

This provider’s code mix and top revenue drivers identify it firmly as an oncology-focused practice with a heavy emphasis on high-cost biologic and immunotherapy infusions. The top revenue codes—J9271 (pembrolizumab), J9144 (daratumumab), and J9299 (nivolumab)—are all oncology injectable agents, and chemotherapy administration codes such as 96413 and add-on infusion codes like 96417 and G0498 appear on the top list, consistent with an infusion-centered practice profile that also orders advanced imaging (78815, 78816, A9552) to support cancer care pathways.

Revenue concentration is highly focused: the precomputed top 3 Medicare codes account for 62.7% of this provider’s total Medicare revenue. In particular, J9271 alone represents $1.3M (36.8% of Medicare revenue) and is the single largest revenue driver, followed by J9144 at $526.7K (15.3%) and J9299 at $364.3K (10.6%).

Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $3.5M and there is no Medicaid billing on file. This means the provider’s revenue exposure and competitive positioning are concentrated in the Medicare market rather than spread across Medicaid, which should be considered when assessing contract leverage, reimbursement sensitivity, and population mix.

For competitive standing on specific drugs, the provider shows a leading national position for pembrolizumab: J9271 ranks #105 of 1841 providers nationally (94th percentile) and is described as "notably above typical national volume for this code," indicating they are a high-volume user of this agent relative to peers. By contrast, J9144 (rank #107 of 615, 82th percentile) and J9299 (rank #241 of 505, 52th percentile) are in more typical ranges, so the provider’s outsize presence is concentrated on particular agents rather than uniformly across all immunotherapies.

The provider’s enrollment history shows sustained tenure: NPI enumerated 2007-05-23 (~19 years ago), indicating a long-standing Medicare billing presence. This longevity, combined with concentrated high-dollar oncology billing, suggests established referral and infusion operations rather than a newly emerging practice.

Several service lines and encounter-level codes are statistical outliers and indicate high operational throughput in certain areas. Evaluation & management codes 99214 and 99215 both rank in the 99th percentile and are labeled as "extreme outlier, far above typical national volume for this code," and venous access device irrigation 96523 ranks #2 of 1643 providers (100th percentile; "extreme outlier"). Additionally, infusion-related codes such as 96413 and 96375 are noted as 98th percentile or similar and labeled "notably above typical national volume," reinforcing unusually high volumes for infusion encounters and device maintenance.

Operational pattern nuance: several codes show very high claim counts but low average payment per claim, indicating throughput of low-reimbursement supportive agents alongside high-revenue biologics. Examples include J0185 with 18.5K claims at $1 avg paid/claim ($18.5K revenue) and J0881 with 10.6K claims at $2 avg paid/claim ($21.3K revenue). These entries suggest the practice administers many low-price supportive medications in parallel with its high-cost oncology infusions.

Imaging and supportive-care services contribute meaningful Medicare revenue and appear integrated into the care pathway. The PET/CT code 78815 generates $297.6K (8.6% of Medicare revenue) and additional imaging and radiotracer codes (78816, A9552) together add further revenue, while supportive drugs such as J0897 (denosumab) account for $234.4K (6.8%), indicating the practice combines systemic therapy with imaging and bone-health management as part of its service mix.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

64 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	31,800	$40	$1.3M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	13,860	$40	$526.7K
J9299	Injection, nivolumab, 1 mg	15,180	$20	$364.3K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	270	$1,100	$297.6K
J0897	Injection, denosumab, 1 mg	13,020	$20	$234.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,560	$90	$140.1K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	4,800	$20	$105.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	840	$100	$82.3K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	530	$130	$68.6K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	610	$90	$57.5K

Showing 1–10 of 64

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 64 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arizona Distribution

Iyad Hamarneh — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arizona

Full comparison — all codes billed, vs. state median

64 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	80	10,000	$40	$487.4K
J9144	6	40	8,370	$40	$349.9K
J9299	6	30	7,480	$20	$290K
J0897	36	260	2,940	$20	$115.6K
78815	14	160	60	$710	$75.8K
Q5118	3	20	1,290	$20	$44.4K
Q5122	1	10	410	$90	$36.5K
J1437	9	20	1,600	$20	$26.5K
96413	11	230	190	$100	$24.8K
J0881	20	50	7,000	$1	$23.1K

Showing 1–10 of 64

Related Providers

Other providers that share a Tax Identification Number (TIN) with Iyad Hamarneh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Arizona Oncology Associates PC	AZ	Specialist	$0	$13.9M
Peter Mathern	AZ	Medical Oncology Physician	$3M	$0
Alan Langerak	AZ	Hematology & Oncology Physician	$2.7M	$0
Charles Taylor	OK	Hematology & Oncology Physician	$2.3M	$0
Allan Espinosa Morazan	AZ	Medical Oncology Physician	$2.2M	$0
Laurie Chen	AZ	Hematology & Oncology Physician	$1.6M	$0
Donn Davis	AZ	Radiation Oncology Physician	$1.2M	$0
Akhilesh Sharma	AZ	Infectious Disease Physician	$1.2M	$0
Sharon Ondreyco	AZ	Hematology & Oncology Physician	$1.1M	$0
Rezwan Chowdhury	AZ	Radiation Oncology Physician	$1.1M	$0

Nearby Providers

Other providers in the same ZIP code as Iyad Hamarneh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Yavapai Community Hospital Association	AZ	General Acute Care Hospital	$0	$66.2M
Prescott Healthcare Solutions LLC	AZ	Family Medicine Physician	$0	$13.3M
Summit Behavioral Health Of Az, LLC	AZ	Substance Abuse Rehabilitation Facility	$0	$13.3M
Medical Services Of Prescott, Inc.	AZ	Emergency Medicine Physician	$0	$12.3M
Prescott Whipple Stage	AZ	Taxi	$0	$9.2M
Prescott Outpatient Surgical Center LLC	AZ	Ambulatory Surgical Clinic/Center	$1.7M	$25.7K
Arizona Institute Of Eye Surgery LLC	AZ	Ambulatory Surgical Clinic/Center	$1.4M	$24.7K
Ayad Agha	AZ	Diagnostic Radiology Physician	$1M	$0
Ajith Purush	AZ	Internal Medicine Physician	$807.3K	$0
Ray Johnson	AZ	Dermatology Physician	$708.7K	$0

Iyad Hamarneh — Billing Profile & Reimbursement Data

Sign up for Iyad Hamarneh — Billing Profile & Reimbursement Data policy alerts

Iyad Hamarneh — Billing Profile & Reimbursement Data

Sign up for Iyad Hamarneh — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References